ET-101 (SynCav1)
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a private, pre-clinical biotech founded in 2019 and based in Cambridge, USA, developing first-in-class gene therapies for neurodegenerative diseases. Its lead candidate, ET-101 (SynCav1), is a gene supplement therapy designed to overexpress Caveolin-1 to promote neuroprotection and synaptic function, with a planned First-in-Human trial in ALS slated for 2025. The company's strategy focuses on pursuing accelerated approvals in rare neurological disorders like ALS, where significant unmet need and compelling preclinical data create a path for rapid development and potential value creation.
View full company profileAbout Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a private, pre-clinical biotech founded in 2019 and based in Cambridge, USA, developing first-in-class gene therapies for neurodegenerative diseases. Its lead candidate, ET-101 (SynCav1), is a gene supplement therapy designed to overexpress Caveolin-1 to promote neuroprotection and synaptic function, with a planned First-in-Human trial in ALS slated for 2025. The company's strategy focuses on pursuing accelerated approvals in rare neurological disorders like ALS, where significant unmet need and compelling preclinical data create a path for rapid development and potential value creation.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |